KCTD10 Activators
KCTD10 Activators are a class of chemical compounds that enhance the functional activity of KCTD10, a protein that is involved in ubiquitination and protein-protein interactions. Some KCTD10 activators, like Forskolin, Rolipram, db cAMP, IBMX, and 8-Bromo-cAMP, increase the levels of cAMP, a secondary messenger in cells. Elevated cAMP levels activate Protein Kinase A (PKA), which can phosphorylate KCTD10, enhancing its functional activity.
Other KCTD10 activators act by triggering compensatory mechanisms that lead to the activation of KCTD10. Compounds like H-89 dihydrochloride, Staurosporine, U0126, PD98059, LY294002, and Rapamycin are inhibitors of various kinases. Their inhibitory actions can stimulate compensatory mechanisms involving other kinases that can phosphorylate and activate KCTD10. For instance, Staurosporine, a non-selective protein kinase inhibitor, can result in compensatory mechanisms that engage other kinases, leading to possible phosphorylation and activation of KCTD10. Similarly, U0126, a selective inhibitor of MEK1 and MEK2, through its inhibitory action, may initiate compensatory mechanisms involving other kinases that can phosphorylate and activate KCTD10. EGF, on the other hand, is a growth factor that can activate the MAPK pathway, leading to the phosphorylation and activation of KCTD10.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin is an adenyl cyclase activator. It leads to the increase of cAMP levels which can activate Protein Kinase A (PKA). PKA can phosphorylate KCTD10 and enhance its functional activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Rolipram is a phosphodiesterase 4 (PDE4) inhibitor. By inhibiting PDE4, Rolipram prevents the breakdown of cAMP, leading to an increase in cAMP levels. Increased cAMP can activate PKA which can phosphorylate and activate KCTD10. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
db cAMP is a cAMP analog. It can activate PKA, leading to the phosphorylation and activation of KCTD10. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-specific phosphodiesterase inhibitor. It can increase cAMP levels, leading to the activation of PKA which can phosphorylate and enhance the functional activity of KCTD10. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
8-Bromo-cAMP is a cell-permeable cAMP analog. It can activate PKA, leading to the phosphorylation and activation of KCTD10. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. However, its action can result in compensatory mechanisms that engage other kinases, leading to possible phosphorylation and activation of KCTD10. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor. Despite its inhibitory action, it can stimulate compensatory mechanisms involving other kinases that can phosphorylate and activate KCTD10. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Its action can trigger compensatory mechanisms involving other kinases that can phosphorylate and activate KCTD10. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. Its action can trigger compensatory mechanisms involving other kinases that can phosphorylate and activate KCTD10. | ||||||